Published online Jun 21, 2007. doi: 10.3748/wjg.v13.i23.3159
Revised: May 2, 2007
Accepted: May 12, 2007
Published online: June 21, 2007
Liver plays a vital role in the production and catabolism of plasma lipoproteins. It depends on the integrity of cellular function of liver, which ensures homeostasis of lipid and lipoprotein metabolism. When liver cancer occurs these processes are impaired and high-density lipoproteins are changed.
- Citation: Jiang JT, Xu N, Wu CP. Metabolism of high density lipoproteins in liver cancer. World J Gastroenterol 2007; 13(23): 3159-3163
- URL: https://www.wjgnet.com/1007-9327/full/v13/i23/3159.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i23.3159
Liver cancer is often followed procession of chronic hepatitis or cirrhosis, therefore hepatic function is damaged obviously on these bases, which may significantly influence lipid and lipoprotein metabolism in vivo[1,2]. In this review we summarized the high density lipoproteins (HDL) metabolism in liver cancer.
HDL are a heterogeneous mixture of spherical macromolecules which differ in size (80-120A), and chemical composition (apolipoprotein A-I, apolipoprotein A-II)[3]. ApoA-Iis present on the majority of HDL particles and constitutes 70% of the apolipoprotein content of HDL particles[4], It is involved in the metabolic interconversions that occur as a result of cholesteryl ester transfer protein (CETP), lecithin: cholesterol acyltransferase (LCAT) and lipase activities and their role in the formation of mature HDL and in reverse cholesterol transport[5]. And Kunitake et al[6] reported that the pre-beta sub-population can be observed directly in fresh plasma by immunoelectrophoresis. It contains phospholipid and free and esterified cholesterol. But, protein constitutes 90% of its mass, and the protein moiety of this subpopulation exhibits markedly lower helicity than that of high density lipoproteins isolated by ultracentrifugation. It was utilized gelose gradient polyacrylamide gel and divided α-HDL to HDL2a, HDL2b and HDL3[7], also in association with a few molecules of sphingomyelin and phosphatidylcholine, β-HDL was divided β1-, pre β2- and pre β3-HDL[8-11].
The majority of the HDL particles contain apoA-I. Differences in the quantitative and qualitative content of lipids, apolipoproteins, enzymes, and lipid transfer proteins result in the presence of various HDL subclasses, which are characterized by differences in shape, density, size, charge, and antigenicity[7]. It is accepted that a low level of HDL cholesterol is an important cardiovascular risk factor[12]. Also, the liver is a major source of the plasma lipoproteins[4]. These data indicate that the putative primary site of human HDL synthesis is in the liver[13,14]. Epidemiological studies have shown that obesity is a risk factor for hepatocellular carcinoma[15].
It is a relative balance in metabolism of cholesterol and lipoprotein under normal liver function, it was influence of metabolism in lipoprotein with liver disease[16], and an impaired lipid metabolism is often found in patients with chronic liver diseases[17]. HL activity is suppressed by estradiol and increased by testosterone[18,19], estradiol to advance in liver cancer, but testicular hormone secrete ability is depressed, it was confirmed that transgenic overexpression of HL in either mice or rabbits decreased HDL-C levels[20,21].
In addition, in the hepatocellular metabolism of long-chain fatty acids suggest that increased fatty acid oxidation by way of extra mitochondrial pathways results in a corresponding increase in the generation of hydrogen peroxide, thus, oxidative stress leads to alterations in gene expression and in DNA itself, which may also contribute to nonneoplastic liver injury and to tumorigenesis in other tissues[22]. As a result of lipid peroxidation probably play significant roles in clonal expansion and hepatocellular carcinoma progression[15]. Liver cancer is frequent malignant tumor, most of them based liver cirrhosis, and hepatic function was damaged obviously, analysis of the cholesterol (Chol) and triglyceride (TG) fractions. Liver diseases were classified into chronic hepatitis (CH), liver cirrhosis (LC), hepatocellular carcinoma (HCC), and metastatic liver cancer, and each fraction was compared among these diseases. Metastatic liver cancer showed a lower HDL-fraction level, but higher levels of the other parameters than HCC. the HDL fraction level in HCC and metastatic liver cancer, and the LDL level in LC and metastatic liver cancer differed between survivors and patients who died. Lipid analysis in liver diseases by this method showed results reflecting the pathologic conditions and may be clinically useful[23].
Reverse cholesterol transport (RCT) is a pathway transporting cholesterol from extrahepatic cells and tissues to the liver, and perhaps intestine, for excretion. That antiport process is determined at least partially by the HDL concentration in the blood[24], uptake of cholesterol from cells by specific acceptors, esterification of cholesterol within HDL by LCAT transfer of cholesterol to the apoB-containing lipoproteins (cholesterol transfer); remodeling of HDL and uptake of HDL cholesterol by the liver and possibly also by kidney and small intestine through lipoprotein receptors[9]. CETP is an important determinant of lipoprotein function, especially high density lipoprotein metabolism, and contributes to the regulation of plasma HDL levels[25]. So high density lipoprotein plays a key role in the reverse cholesterol transport pathway in liver[26,27].
The liver contributes free cholesterol to the plasma lipoproteins which participate in the process of reverse-cholesterol transport. But when cells were incubated with equivalent concentrations of isolated lipoproteins, HDL was much more effective in promoting [14C] cholesterol efflux than LDL, suggesting that unesterified cholesterol is initially transferred to HDL and then to LDL[28]. Serum concentrations of apolipoprotein A-Iand A-II were determined in patients with hepatic metastases of colorectal cancer, with primary liver cancer and with cirrhosis. In all three liver diseases, the HDL fraction and apolipoproteins A-Iand A-II showed significantly low values[29]. To establish whether there is any significant relationship between high-density lipoprotein cholesterol concentrations and biopsy-documented liver disease, 169 patients had needle biopsies, serum cholesterol, and HDLC evaluated. In both men and women, HDLC decreased strikingly and significantly in acute alcoholic hepatitis and in acute viral hepatitis, compared to controls. Men and women with inactive alcoholic liver disease and chronic active hepatitis showed moderate decreased in HDLC. Patients with primary and metastatic hepatic neoplasms also had strikingly decreased HDLC[30].
Hepatoma cell lines serve as a suitable model for the study of hepatic receptors for lipoprotein in man[31]. The experiments also demonstrate that the responses at least of some of the receptors of the hepatoma cells in culture resemble those of hepatocytes in vivo and in vitro[32].
The importance of hepatic apolipoprotein (apo) E in lipoprotein metabolism is evidenced by the fact that the level of apoE expression determines the fate of LDL and HDL3[33]. Although studies in recombinant cells indicate that scavenger receptor class B, typeI(SR-BI) can promote cholesterol efflux, investigations in transgenic mice overexpressing or deficient in SR-BI support its physiological function as selectively sequestering cholesteryl esters from high density lipoproteins[34].
Impaired capacity of acute-phase high density lipoprotein particles to deliver cholesteryl ester to the hepatoma cell line[35] suggest that plasma high-density lipoproteins are cleared from the circulation by specific receptors and are either totally degraded or their cholesteryl esters are selectively, delivered to cells by receptors such as the scavenger receptor class B typeI(SR-BI)[36]. The fact that the capacity for cellular cholesterol efflux from HUH-7 cells is slightly impaired by AP-HDL (compared with HDL) is supports the concept that scavenger receptor class B, typeI(SR-BI), of the human hepatoma cell line, increased HDL binding with cholesterol loading that was specific for HDL3, and hepatic tissue can modulate its recognition of HDL. Hepatic membranes from a patient lacking normal hepatic LDL receptors bound apo A-IHDL normally. These data indicate that a saturable, specific regulatable receptor for apo E-free HDL is present in human liver[37].
Lipids or proteins of α-HDL are removed from the circulation by at least 2 direct pathways, which involve the selective uptake of lipids by scavenger receptor B1 (SR-BI) and the holoparticle uptake by apoE or apoA-Ireceptors[38-41]. ApoE-containing HDLs, which constitute the minority of HDLs, are internalized by hepatic apoE receptors (LDL receptor and LDL receptor-related protein)[42]. Tall and colleagues have suggested the presence of a hepatic leptin-regulated HDL receptor, which regulates HDL-C levels by mediating holoparticle uptake into liver cells[43].
HDL plays a key role in the lipids of binding and delivery, and is a key enzyme in lipoprotein adjustment. Hepatic lipase (HL) hydrolyzes phospholipids and triglycerides in all lipoprotein classes[44,45]. HL is a lipolytic enzyme involved in the metabolism of plasma lipoproteins, especially HDLs[46].
Genetic factors have been shown to play an important role in determining interindividual variation in plasma HDL-C levels[47]. HL may hydrolyze phospholipids of surface layers from HDL and plasma membrane and thereby enable the flux of cholesteryl esters from the lipoprotein core into the plasma membrane[48,49].
It is important role of hepatic triacylglycerol lipase (H-TGL) in promoting the liver uptake of HDL free and esterified cholesterol[50]. But hepatic lipase can enhance the delivery of high-density lipoprotein cholesterol to cells by a process which does not involve apoprotein catabolism[51]. Hepatic lipase (HL) gene transcription is almost exclusively limited to hepatocytes[52]. Hepatic lipase mediates an increase in selective uptake of high-density lipoprotein-associated cholesteryl esters[53]. Approximately 28% of the HDL phosphatidylcholine was hydrolyzed by the hepatic lipase. The stimulation of free cholesterol delivery was dose-dependent up to a level of 100 micrograms of HDL free cholesterol/ml of extracellular medium, and was directly related to the extent of phosphatidylcholine hydrolysis. The enhanced cellular accumulation of HDL free cholesterol observed with hepatic lipase appears to be due to the phospholipase activity of this enzyme[54].
Hepatic lipase stimulates the internalization of apoprotein (apo) B-containing lipoproteins by hepatocytes independent from lipolysis. In this study, the role of HL in the hepatic metabolism of apo A-I-containing lipoproteins, i.e. HDL, was investigated. To explore the role of these molecules for the HL effect on selective CE uptake, hepatoma cells were depleted of proteoglycans or Chinese hamster ovary (CHO) cells deficient in proteoglycan synthesis were used. Proteoglycan-deficiency reduced the HL-mediated increase in selective uptake by more than 80%[53].
The inverse correlation between HL activity and HDL-C[55], is due to hepatic lipase stimulation of the uptake of high density lipoprotein cholesterol by hepatoma cells[54]. Hepatoma cells exposed to hepatic lipase-modified HDL, showed an increased uptake of HDL free cholesterol relative to cells exposed to control HDL[30].
Protien kinase C is a key molecule in signal transduction pathway, and significant control role in cell growth and deterioration[56]. It plays an important role in many of HDL effects on cells[57]. There is close correlation between carcinogenesis in liver and abnormalities in PKC-α abnormality expression[58,59]. HDL receptor-mediated translocation and efflux of intracellular cholesterol occurs through activation of protein kinase C[60]. Activation of protein kinase C enhances and inhibition of PKC suppresses apolipoprotein-mediated cholesterol efflux[60,61]. High density lipoprotein stimulates multiple signaling pathways. HDL-induced activation of the mitogen-activated protein kinase (MAPK) pathway can be mediated by protein kinase C[62], and high expression in liver tissue[56].
The liver plays a vital role in the production and clearance of a large number of lipoproteins and is an important determinant of the plasma levels of various lipids[63]. Lipid analysis in liver diseases by this method showed results reflecting the pathologic conditions and may be clinically useful[23]. It may be a good indicator of the hepatic protein synthetic ability during the perioperative period after hepatectomy[64]. Drinking instant coffee powder, in addition to increased uptake HDL-cholesterol, resulted in amelioration of abnormal lipoprotein profiles occurred in hepatoma-bearing rats and has the ability to induce cell cycle arrest and apoptosis in hepatoma cells and to suppress tumor cell invasion. It could also exhibit these effects that lead to the inhibition of tumor growth and metastases[65]. High density lipoprotein as a potential carrier for delivery of a lipophilic antitumoral drug into hepatoma cells[66], to supply a new treatment method in liver cancer.
S- Editor Liu Y L- Editor Alpini GD E- Editor Wang HF
1. | Jiang J, Nilsson-Ehle P, Xu N. Influence of liver cancer on lipid and lipoprotein metabolism. Lipids Health Dis. 2006;5:4. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 126] [Cited by in F6Publishing: 131] [Article Influence: 7.3] [Reference Citation Analysis (0)] |
2. | Tietge UJ, Boker KH, Bahr MJ, Weinberg S, Pichlmayr R, Schmidt HH, Manns MP. Lipid parameters predicting liver function in patients with cirrhosis and after liver transplantation. Hepatogastroenterology. 1998;45:2255-2260. [PubMed] [Cited in This Article: ] |
3. | Assmann G, Schriewer H. HDL cholesterol: biochemical aspects (author's transl). Klin Wochenschr. 1980;58:749-756. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis (0)] |
4. | Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 2005;96:1221-1232. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 724] [Cited by in F6Publishing: 689] [Article Influence: 36.3] [Reference Citation Analysis (0)] |
5. | Skinner ER. High-density lipoprotein subclasses. Curr Opin Lipidol. 1994;5:241-247. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 1.6] [Reference Citation Analysis (0)] |
6. | Kunitake ST, La Sala KJ, Kane JP. Apolipoprotein A-I-containing lipoproteins with pre-beta electrophoretic mobility. J Lipid Res. 1985;26:549-555. [PubMed] [Cited in This Article: ] |
7. | von Eckardstein A, Huang Y, Assmann G. Physiological role and clinical relevance of high-density lipoprotein subclasses. Curr Opin Lipidol. 1994;5:404-416. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 122] [Cited by in F6Publishing: 124] [Article Influence: 4.1] [Reference Citation Analysis (0)] |
8. | Barrans A, Jaspard B, Barbaras R, Chap H, Perret B, Collet X. Pre-beta HDL: structure and metabolism. Biochim Biophys Acta. 1996;1300:73-85. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 2.5] [Reference Citation Analysis (0)] |
9. | Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res. 1995;36:211-228. [PubMed] [Cited in This Article: ] |
10. | Asztalos BF, Sloop CH, Wong L, Roheim PS. Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations. Biochim Biophys Acta. 1993;1169:291-300. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 192] [Cited by in F6Publishing: 190] [Article Influence: 6.1] [Reference Citation Analysis (0)] |
11. | Castro GR, Fielding CJ. Early incorporation of cell-derived cholesterol into pre-beta-migrating high-density lipoprotein. Biochemistry. 1988;27:25-29. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 547] [Cited by in F6Publishing: 565] [Article Influence: 15.7] [Reference Citation Analysis (0)] |
12. | Gordon DJ, Rifkind BM. High-density lipoprotein--the clinical implications of recent studies. N Engl J Med. 1989;321:1311-1316. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1175] [Cited by in F6Publishing: 1153] [Article Influence: 32.9] [Reference Citation Analysis (0)] |
13. | Eggerman TL, Hoeg JM, Meng MS, Tombragel A, Bojanovski D, Brewer HB. Differential tissue-specific expression of human apoA-I and apoA-II. J Lipid Res. 1991;32:821-828. [PubMed] [Cited in This Article: ] |
14. | Garcia A, Barbaras R, Collet X, Bogyo A, Chap H, Perret B. High-density lipoprotein 3 receptor-dependent endocytosis pathway in a human hepatoma cell line (HepG2). Biochemistry. 1996;35:13064-13071. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.0] [Reference Citation Analysis (0)] |
15. | Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology. 2004;127:S97-S103. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 286] [Cited by in F6Publishing: 306] [Article Influence: 15.3] [Reference Citation Analysis (0)] |
16. | Davis R, Bryson HM. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs. 1994;47:677-700. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 199] [Cited by in F6Publishing: 217] [Article Influence: 7.2] [Reference Citation Analysis (0)] |
17. | Cicognani C, Malavolti M, Morselli-Labate AM, Zamboni L, Sama C, Barbara L. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Arch Intern Med. 1997;157:792-796. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 137] [Cited by in F6Publishing: 144] [Article Influence: 5.3] [Reference Citation Analysis (0)] |
18. | Brinton EA. Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein A-I and lowers hepatic lipase activity without lowering the fractional catabolic rate. Arterioscler Thromb Vasc Biol. 1996;16:431-440. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 78] [Cited by in F6Publishing: 73] [Article Influence: 2.6] [Reference Citation Analysis (0)] |
19. | Tan KC, Shiu SW, Pang RW, Kung AW. Effects of testosterone replacement on HDL subfractions and apolipoprotein A-I containing lipoproteins. Clin Endocrinol (Oxf). 1998;48:187-194. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 2.2] [Reference Citation Analysis (0)] |
20. | Busch SJ, Barnhart RL, Martin GA, Fitzgerald MC, Yates MT, Mao SJ, Thomas CE, Jackson RL. Human hepatic triglyceride lipase expression reduces high density lipoprotein and aortic cholesterol in cholesterol-fed transgenic mice. J Biol Chem. 1994;269:16376-16382. [PubMed] [Cited in This Article: ] |
21. | Santamarina-Fojo S, Haudenschild C, Amar M. The role of hepatic lipase in lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol. 1998;9:211-219. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 174] [Cited by in F6Publishing: 161] [Article Influence: 6.2] [Reference Citation Analysis (0)] |
22. | Ockner RK, Kaikaus RM, Bass NM. Fatty-acid metabolism and the pathogenesis of hepatocellular carcinoma: review and hypothesis. Hepatology. 1993;18:669-676. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 87] [Cited by in F6Publishing: 82] [Article Influence: 2.6] [Reference Citation Analysis (1)] |
23. | Ooi K, Shiraki K, Sakurai Y, Morishita Y, Nobori T. Clinical significance of abnormal lipoprotein patterns in liver diseases. Int J Mol Med. 2005;15:655-660. [PubMed] [Cited in This Article: ] |
24. | Sviridov D, Nestel P. Dynamics of reverse cholesterol transport: protection against atherosclerosis. Atherosclerosis. 2002;161:245-254. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 109] [Cited by in F6Publishing: 112] [Article Influence: 5.1] [Reference Citation Analysis (0)] |
25. | Hirano R, Igarashi O, Kondo K, Itakura H, Matsumoto A. Regulation by long-chain fatty acids of the expression of cholesteryl ester transfer protein in HepG2 cells. Lipids. 2001;36:401-406. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.1] [Reference Citation Analysis (0)] |
26. | Sviridov D, Sasahara T, Pyle LE, Nestel PJ, Fidge NH. Antibodies against high-density lipoprotein binding proteins enhance high-density lipoprotein uptake but do not affect cholesterol efflux from rat hepatoma cells. Int J Biochem Cell Biol. 1997;29:583-588. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis (0)] |
27. | Genest JJ, McNamara JR, Ordovas JM, Martin-Munley S, Jenner JL, Millar J, Salem DN, Schaefer EJ. Effect of elective hospitalization on plasma lipoprotein cholesterol and apolipoproteins A-I, B and Lp(a). Am J Cardiol. 1990;65:677-679. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 0.6] [Reference Citation Analysis (0)] |
28. | Sviridov D, Fidge N. Pathway of cholesterol efflux from human hepatoma cells. Biochim Biophys Acta. 1995;1256:210-220. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 0.9] [Reference Citation Analysis (0)] |
29. | Hachem H, Favre G, Raynal G, Blavy G, Canal P, Soula G. Serum apolipoproteins A-I, A-II and B in hepatic metastases. Comparison with other liver diseases: hepatomas and cirrhosis. J Clin Chem Clin Biochem. 1986;24:161-166. [PubMed] [Cited in This Article: ] |
30. | Kanel GC, Radvan G, Peters RL. High-density lipoprotein cholesterol and liver disease. Hepatology. 1983;3:343-348. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 0.8] [Reference Citation Analysis (0)] |
31. | Wadsack C, Hirschmugl B, Hammer A, Levak-Frank S, Kozarsky KF, Sattler W, Malle E. Scavenger receptor class B, type I on non-malignant and malignant human epithelial cells mediates cholesteryl ester-uptake from high density lipoproteins. Int J Biochem Cell Biol. 2003;35:441-454. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 1.1] [Reference Citation Analysis (0)] |
32. | Tamai T, Patsch W, Schonfeld G. Regulation of lipoprotein receptors on a rat hepatoma cell line. Atherosclerosis. 1988;69:29-37. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis (0)] |
33. | Charpentier D, Tremblay C, Rassart E, Rhainds D, Auger A, Milne RW, Brissette L. Low- and high-density lipoprotein metabolism in HepG2 cells expressing various levels of apolipoprotein E. Biochemistry. 2000;39:16084-16091. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis (0)] |
34. | Mulcahy JV, Riddell DR, Owen JS. Human scavenger receptor class B type II (SR-BII) and cellular cholesterol efflux. Biochem J. 2004;377:741-747. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 1.5] [Reference Citation Analysis (0)] |
35. | Artl A, Marsche G, Pussinen P, Knipping G, Sattler W, Malle E. Impaired capacity of acute-phase high density lipoprotein particles to deliver cholesteryl ester to the human HUH-7 hepatoma cell line. Int J Biochem Cell Biol. 2002;34:370-381. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 1.3] [Reference Citation Analysis (0)] |
36. | Huard K, Bourgeois P, Rhainds D, Falstrault L, Cohn JS, Brissette L. Apolipoproteins C-II and C-III inhibit selective uptake of low- and high-density lipoprotein cholesteryl esters in HepG2 cells. Int J Biochem Cell Biol. 2005;37:1308-1318. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis (0)] |
37. | Hoeg JM, Demosky SJ, Edge SB, Gregg RE, Osborne JC, Brewer HB. Characterization of a human hepatic receptor for high density lipoproteins. Arteriosclerosis. 1985;5:228-237. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 86] [Cited by in F6Publishing: 92] [Article Influence: 2.4] [Reference Citation Analysis (0)] |
38. | Krieger M. Charting the fate of the "good cholesterol": identification and characterization of the high-density lipoprotein receptor SR-BI. Annu Rev Biochem. 1999;68:523-558. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 412] [Cited by in F6Publishing: 401] [Article Influence: 16.7] [Reference Citation Analysis (0)] |
39. | Trigatti B, Rigotti A, Krieger M. The role of the high-density lipoprotein receptor SR-BI in cholesterol metabolism. Curr Opin Lipidol. 2000;11:123-131. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 156] [Cited by in F6Publishing: 162] [Article Influence: 6.8] [Reference Citation Analysis (0)] |
40. | Curtiss LK, Boisvert WA. Apolipoprotein E and atherosclerosis. Curr Opin Lipidol. 2000;11:243-251. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 168] [Cited by in F6Publishing: 177] [Article Influence: 7.4] [Reference Citation Analysis (0)] |
41. | Tall AR, Jiang Xc, Luo Y, Silver D. 1999 George Lyman Duff memorial lecture: lipid transfer proteins, HDL metabolism, and atherogenesis. Arterioscler Thromb Vasc Biol. 2000;20:1185-1188. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 98] [Cited by in F6Publishing: 102] [Article Influence: 4.3] [Reference Citation Analysis (0)] |
42. | Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622-630. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 2791] [Cited by in F6Publishing: 2890] [Article Influence: 80.3] [Reference Citation Analysis (0)] |
43. | Silver DL, Wang N, Tall AR. Defective HDL particle uptake in ob/ob hepatocytes causes decreased recycling, degradation, and selective lipid uptake. J Clin Invest. 2000;105:151-159. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 95] [Cited by in F6Publishing: 97] [Article Influence: 4.0] [Reference Citation Analysis (0)] |
44. | Cohen JC, Vega GL, Grundy SM. Hepatic lipase: new insights from genetic and metabolic studies. Curr Opin Lipidol. 1999;10:259-267. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 110] [Cited by in F6Publishing: 113] [Article Influence: 4.5] [Reference Citation Analysis (0)] |
45. | Thuren T. Hepatic lipase and HDL metabolism. Curr Opin Lipidol. 2000;11:277-283. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 79] [Cited by in F6Publishing: 84] [Article Influence: 3.5] [Reference Citation Analysis (0)] |
46. | Su Z, Zhang S, Nebert DW, Zhang L, Huang D, Hou Y, Liao L, Xiao C. A novel allele in the promoter of the hepatic lipase is associated with increased concentration of HDL-C and decreased promoter activity. J Lipid Res. 2002;43:1595-1601. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis (0)] |
47. | Cohen JC, Wang Z, Grundy SM, Stoesz MR, Guerra R. Variation at the hepatic lipase and apolipoprotein AI/CIII/AIV loci is a major cause of genetically determined variation in plasma HDL cholesterol levels. J Clin Invest. 1994;94:2377-2384. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 120] [Cited by in F6Publishing: 117] [Article Influence: 3.9] [Reference Citation Analysis (0)] |
48. | Lambert G, Chase MB, Dugi K, Bensadoun A, Brewer HB, Santamarina-Fojo S. Hepatic lipase promotes the selective uptake of high density lipoprotein-cholesteryl esters via the scavenger receptor B1. J Lipid Res. 1999;40:1294-1303. [PubMed] [Cited in This Article: ] |
49. | Collet X, Tall AR, Serajuddin H, Guendouzi K, Royer L, Oliveira H, Barbaras R, Jiang XC, Francone OL. Remodeling of HDL by CETP in vivo and by CETP and hepatic lipase in vitro results in enhanced uptake of HDL CE by cells expressing scavenger receptor B-I. J Lipid Res. 1999;40:1185-1193. [PubMed] [Cited in This Article: ] |
50. | Dugi KA, Vaisman BL, Sakai N, Knapper CL, Meyn SM, Brewer HB, Santamarina-Fojo S. Adenovirus-mediated expression of hepatic lipase in LCAT transgenic mice. J Lipid Res. 1997;38:1822-1832. [PubMed] [Cited in This Article: ] |
51. | Bamberger M, Lund-Katz S, Phillips MC, Rothblat GH. Mechanism of the hepatic lipase induced accumulation of high-density lipoprotein cholesterol by cells in culture. Biochemistry. 1985;24:3693-3701. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 105] [Cited by in F6Publishing: 111] [Article Influence: 2.8] [Reference Citation Analysis (0)] |
52. | Chang SF, Scharf JG, Will H. Structural and functional analysis of the promoter of the hepatic lipase gene. Eur J Biochem. 1997;247:148-159. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis (0)] |
53. | Rinninger F, Mann WA, Kaiser T, Ahle S, Meyer N, Greten H. Hepatic lipase mediates an increase in selective uptake of high-density lipoprotein-associated cholesteryl esters by human Hep 3B hepatoma cells in culture. Atherosclerosis. 1998;141:273-285. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 0.9] [Reference Citation Analysis (0)] |
54. | Bamberger M, Glick JM, Rothblat GH. Hepatic lipase stimulates the uptake of high density lipoprotein cholesterol by hepatoma cells. J Lipid Res. 1983;24:869-876. [PubMed] [Cited in This Article: ] |
55. | Dugi KA, Brandauer K, Schmidt N, Nau B, Schneider JG, Mentz S, Keiper T, Schaefer JR, Meissner C, Kather H. Low hepatic lipase activity is a novel risk factor for coronary artery disease. Circulation. 2001;104:3057-3062. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 75] [Cited by in F6Publishing: 77] [Article Influence: 3.3] [Reference Citation Analysis (0)] |
56. | Carter CA. Protein kinase C as a drug target: implications for drug or diet prevention and treatment of cancer. Curr Drug Targets. 2000;1:163-183. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 61] [Cited by in F6Publishing: 66] [Article Influence: 2.8] [Reference Citation Analysis (0)] |
57. | Deeg MA, Bowen RF, Oram JF, Bierman EL. High density lipoproteins stimulate mitogen-activated protein kinases in human skin fibroblasts. Arterioscler Thromb Vasc Biol. 1997;17:1667-1674. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 1.2] [Reference Citation Analysis (0)] |
58. | Tu LC, Chou CK, Chen HC, Yeh SF. Protein kinase C-mediated tyrosine phosphorylation of paxillin and focal adhesion kinase requires cytoskeletal integrity and is uncoupled to mitogen-activated protein kinase activation in human hepatoma cells. J Biomed Sci. 2001;8:184-190. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 0.8] [Reference Citation Analysis (0)] |
59. | Perletti G, Tessitore L, Sesca E, Pani P, Dianzani MU, Piccinini F. Epsilon PKC acts like a marker of progressive malignancy in rat liver, but fails to enhance tumorigenesis in rat hepatoma cells in culture. Biochem Biophys Res Commun. 1996;221:688-691. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 0.5] [Reference Citation Analysis (0)] |
60. | Mendez AJ, Oram JF, Bierman EL. Protein kinase C as a mediator of high density lipoprotein receptor-dependent efflux of intracellular cholesterol. J Biol Chem. 1991;266:10104-10111. [PubMed] [Cited in This Article: ] |
61. | Francis GA, Tsujita M, Terry TL. Apolipoprotein AI efficiently binds to and mediates cholesterol and phospholipid efflux from human but not rat aortic smooth muscle cells. Biochemistry. 1999;38:16315-16322. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 0.7] [Reference Citation Analysis (0)] |
62. | Grewal T, de Diego I, Kirchhoff MF, Tebar F, Heeren J, Rinninger F, Enrich C. High density lipoprotein-induced signaling of the MAPK pathway involves scavenger receptor type BI-mediated activation of Ras. J Biol Chem. 2003;278:16478-16481. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 59] [Cited by in F6Publishing: 64] [Article Influence: 3.0] [Reference Citation Analysis (0)] |
63. | Cooper ME, Akdeniz A, Hardy KJ. Effects of liver transplantation and resection on lipid parameters: a longitudinal study. Aust N Z J Surg. 1996;66:743-746. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.5] [Reference Citation Analysis (0)] |
64. | Katsuramaki T, Hirata K, Kimura Y, Nagayama M, Meguro M, Kimura H, Honma T, Furuhata T, Hideki U, Hata F. Changes in serum levels of apolipoprotein A-1 as an indicator of protein metabolism after hepatectomy. Wound Repair Regen. 2002;10:77-82. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis (0)] |
65. | Miura Y, Ono K, Okauchi R, Yagasaki K. Inhibitory effect of coffee on hepatoma proliferation and invasion in culture and on tumor growth, metastasis and abnormal lipoprotein profiles in hepatoma-bearing rats. J Nutr Sci Vitaminol (Tokyo). 2004;50:38-44. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.0] [Reference Citation Analysis (0)] |
66. | Lou B, Liao XL, Wu MP, Cheng PF, Yin CY, Fei Z. High-density lipoprotein as a potential carrier for delivery of a lipophilic antitumoral drug into hepatoma cells. World J Gastroenterol. 2005;11:954-959. [PubMed] [Cited in This Article: ] |